Avoid Glucagon Confusion: Know Where It’s Produced
Title: Avoid Glucagon Confusion: Know Where It’s Produced Abstract: Glucagon, a 29-amino-acid peptide hormone, is exclusively produced in the pancreatic alpha cells. Misunderstanding its origin leads to clinical errors in hypoglycemia management. Current market trends show a 7.2% CAGR (2023–2030) for synthetic glucagon analogs, driven by nasal and injectable formats. Leading brands (e.g., Baqsimi, GlucaGen) differ in stability and onset time (5–15 min). Key technical advantages include rapid glycogenolysis; disadvantages include short half-life (<10 min). Product selection requires verifying GMP-certified facilities (e.g., FDA, EMA) and cold-chain logistics (2–8°C). Industry data indicates 85% of hospital errors stem from origin confusion. Prioritize brands with documented purity (>98%) and third-party potency assays.